Oncology Precision Medicine Market Share, Global Industry Size, Trends, Technology, and Analysis by 2035 This report presents a detailed, data-driven analysis of the global Oncology Precision Medicine Market size, offering insights into historical performance, current dynamics, and projections from 2025 to 2035. With a strong emphasis on factual assessment, the report refrains from speculative assumptions and aims to support business decisions through accurate forecasting and strategic intelligence. I recently came across a report by Roots Analysis that really put things into perspective. According to them, The oncology precision medicine market, valued at USD 166 billion in 2025, is project to reach USD 185 billion in 2026 and USD 364 billion by 2035, representing a CAGR of 7.8% during the forecast period 2026 to 2035. Market Segmentation - Historical Trend: Since 2018 - Forecast Period: Till 2035 - Market Size 2026: USD 185 Billion - Market Size 2035: USD 364 Billion - CAGR (Till 2035): 7.8% - Type of Cancer Targeted • Bladder Cancer • Blood / Hematologic Cancer • Breast Cancer • Cervical Cancer • Gastrointestinal Cancer • Head and Neck Squamous Cell Cancer • Lung Cancer • Skin Cancer • Others - Route of Administration • Oral • Intravenous • Others - Type of Molecule • Small Molecules • Biologics - Drug Class • Kinase Inhibitors • Enzyme Inhibitors • Immune Checkpoint Inhibitors • Others - Leading Drug Developers • Merck • Pfizer • AstraZeneca • Johnson $ Johnson Innovative Medicine • Genentech - Key Geographical Regions • North America ( • Europe ( • Asia ( • Middle East and North Africa ( • Latin America ( - Key Players • AbbVie • Anticancer Bioscience • Astellas Pharma • Astrazeneca • Bayer • Blueprint Medicines • Bristol Myers Squibb • Eli Lilly • Erasca • Genentech • GlaxoSmithKline • Hutchmed • IDEAYA Biosciences • Jiangsu Hengrui Pharmaceuticals • Johnson & Johnson Innovative Medicine • Merck • Novartis • Pfizer • Repare Therapeutics • Roche • Seagen • SpringWorks Therapeutics • Takeda Pharmaceutical • VERAXA Biotech GmbH • VRise Therapeutics - PowerPoint Presentation (Complimentary): Available - Customization Scope: 15% Free Customization - Excel Data Packs (Complimentary) • Market Landscape • Partnerships and Collaborations • Clinical Trial Analysis • Case Study: Oncology Precision Medicine Assay Kits • Market Forecast and Opportunity Analysis Read More: https://www.rootsanalysis.com/reports/oncology-precision-medicine-market.html

Chronic Kidney Diseases Market Size, Demand, Analytical Overview, Comprehensive Analysis, Segmentation, Competitive Landscape 2035 Roots Analysis recently published a report on the global Chronic Kidney Disease Market growth. With a focus on historical trends, current developments, and future projections, it offers a data-rich foundation for decision-makers, industry participants, and investors. The report includes both macro and micro-level insights, enabling readers to grasp key dynamics across segments, regions, and product categories. Market Size and Forecast Current Market Size:USD 67.36 billion Future Market Size: CAGR: 5.12% Market Overview This growth is calculated based on observed trends, actual industry performance, and current developments in product usage and adoption. The study takes into account the challenges faced by key players and the general market structure, while avoiding speculative interpretations. It focuses on providing a clear picture of market performance across different regions and segments. This report supports strategic planning by delivering verified data, cross-segment comparisons, and actionable insights—available in both PDF and spreadsheet formats for ease of integration. Market Scope and Segmentation - Historical Trend: Since 2019 - Forecast Period: Till 2035 - Market Size 2035: USD 67.36 billion - Market CAGR (Till 2035): 5.12% - Type of Drug Class • ACE Inhibitors • Angiotensin-II Receptor Blockers • Calcium Channel Blockers • Beta Blockers • Erythropoiesis-stimulating Agents • Diuretics • Other Drug Classes - Type of Molecule • Small Molecules • Biologics - Type of Treatment • Drugs • Dialysis • Kidney Transplant - Type of Disease Indication • Diabetic Nephropathy • Glomerulonephritis • Hypertensive Nephropathy • Polycystic Kidney Disease • Other Indications - Route of Administration • Oral • Parenteral - End User • Hospitals and Clinics • Ambulatory Surgery Centers • Dialysis Centers - Geographical Regions • North America ( • Europe ( • Asia Pacific ( • Middle East and North Africa ( • Latin America ( - Key Companies Profiled • AbbVie • Amgen • Abbott • AstraZeneca • Akebia Therapeutics • Bristol-Myers Squibb • Fresenius Medical Care • FibroGen • GlaxoSmithKline • Johnson & Johnson • Kissei Pharmaceutical • Merck • Novartis • Otsuka Pharmaceutical • Pfizer • LA Roche • Sanofi • Siemens Healthcare • Teva Pharmaceutical - PowerPoint PresentationComplimentary): Available - Customization Scope: 15% Free Customization - Excel Data Packs(Complimentary): Available Read More: https://www.rootsanalysis.com/reports/chronic-kidney-disease-market/235.html